Abstract
PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Current Pharmaceutical Design
Title: PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Volume: 15 Issue: 30
Author(s): D. Kouvelas, A. Goulas, G. Papazisis, C. Sardeli and C. Pourzitaki
Affiliation:
Keywords: PDE5 inhibitors, sildenafil, vardenafil, tadafil
Abstract: PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors – sildenafil (Viagra®), vardenafil (Levitra®) and tadalafil (Cialis®) - are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio®) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena®), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.
Export Options
About this article
Cite this article as:
Kouvelas D., Goulas A., Papazisis G., Sardeli C. and Pourzitaki C., PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile, Current Pharmaceutical Design 2009; 15 (30) . https://dx.doi.org/10.2174/138161209789206971
DOI https://dx.doi.org/10.2174/138161209789206971 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets News in the Indications of Direct Oral Anticoagulants According to the American College of Chest Physicians 2016 Guidelines
Current Drug Metabolism 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents In silico Analysis of Toxins of Staphylococcus aureus for Validating Putative Drug Targets
Infectious Disorders - Drug Targets Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design The Renin-Angiotensin System: New Insight into Old Therapies
Current Medicinal Chemistry Inducible Nitric Oxide Synthase - Time for Reappraisal
Current Drug Targets - Inflammation & Allergy Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry Traditional Chinese Medicine - Sea Urchin
Mini-Reviews in Medicinal Chemistry Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Toward a Discipline of Pharmacoepigenomics
Current Pharmacogenomics Growing Burden of Diabetes in Sub- Saharan Africa: Contribution of Pesticides ?
Current Diabetes Reviews Genetics and Personalized Medicine in Antidepressant Treatment
Current Pharmaceutical Design Action Mechanism of Antihistamines and the New Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Pharmacogenomics and Severe Infections: The Role of the Genomes of Both the Host and the Pathogen
Current Pharmacogenomics Cyclopentenone Prostaglandins as Anti-Inflammatory Agents: A Novel Therapeutic Strategy?
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents